hypogonadism
Conditions
Interventions
None listed
Sponsors
Teikyo University Hospital
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: No restrictions were placed on article types or publication language. To be included, a study had to meet the following criteria: 1) It was a placebo-controlled randomized trial; 2) It involved patients with hypogonadism; and 3) The treatment duration was more than 24 weeks or six months.
Exclusion criteria
Exclusion criteria: Exclusion criteria were: 1) treatment with supplements; 2) not being a randomized controlled trial (RCT); and 3) insufficient data.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome was the change in body composition. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary outcomes included skeletal and muscle function (risk of fracture, handgrip strength, and forearm bone mineral density [BMD]) and metabolism (high-density lipoprotein cholesterol [HDL], low-density lipoprotein cholesterol [LDL], triglycerides [TG], and homeostatic model assessment for insulin resistance [HOMA-R] for patients with type 2 diabetes mellitus [T2DM]). | — |
Countries
Japan,North America
Contacts
Public ContactRyusuke Ochiai
Teikyo University Hospital Department of Oncology
Outcome results
None listed